Atara Biotherapeutics Inc
NASDAQ:ATRA
Atara Biotherapeutics Inc
NASDAQ:ATRA
Price:
0.6036 USD
Market Closed
Updated:
May 17, 2024
Atara Biotherapeutics Inc
Accounts Receivables
|
Atara Biotherapeutics Inc
Accounts Receivables Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Atara Biotherapeutics Inc
NASDAQ:ATRA
|
Accounts Receivables
$35.8m
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Receivables
$11.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Receivables
$4.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Receivables
$6.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Receivables
$1.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
31%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Receivables
$5.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
See Also
What is Atara Biotherapeutics Inc's Accounts Receivables?
Accounts Receivables
35.8m
USD
35.8m
USD
Based on the financial report for Mar 31, 2024, Atara Biotherapeutics Inc's Accounts Receivables amounts to 35.8m USD.
What is Atara Biotherapeutics Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
55%
55%
Over the last year, the Accounts Receivables growth was 8 859%. The average annual Accounts Receivables growth rates for Atara Biotherapeutics Inc have been 55% over the past three years .
You don't have any saved screeners yet
